March 17, 2025

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen
312-265-9574
bsorensen@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Revelation Bios (REVB-NASDAQ)

REVB: Study Shows Positive Results

Revelation Biosciences is a life sciences company whose focus is the development of immunologic-based therapies. We value REVB at $21.45 using the comparable method involving companies with similar characteristics.

Current Price (03/14/25)	$3.40
Valuation	**$21.45**

OUTLOOK

Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system.

The company announced that a study on its flagship Gemini treatment showed the drug reduces inflammation in human blood cells. These results hold great promise for the treatment of conditions such as CKD (chronic kidney disease).

SUMMARY DATA

52-Week High	**$49.92**
52-Week Low	**$3.27**
One-Year Return (%)	**-91.18**
Beta	**0.17**
Average Daily Volume (sh)	**61,184**
Shares Outstanding (mil)	**0**
Market Capitalization ($mil)	**$3**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**13**
Insider Ownership (%)	**0**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**

Risk Level	**High**
Type of Stock	**Small-Value**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2022	NR	NR	NR	NR	0 A
2023	0 A	0 A	0 A	0 A	0 A
2024	0 A	0 A	0 A	0 A	0 A
2025	0 E	0 E	0 E	0 E	0 E

Earnings Per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2022	NR	NR	NR	NR	-20.09 A
2023	1.96 A	-0.25 A	-0.26 A	-8.33 A	-10.80 E
2024	-2.46A	-5.13A	-0.84A	-10.06A	-87.68E
2025	-10.00E	-10.00E	-11.00E	-7.90E	-38.90E

*numbers don't add due to reverse stock split

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

Update

Revelation Biosciences (REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The impact of PHAD on the immune system has been studied over multiple years and has been shown to have a positive effect on the human immune system. The company's current therapeutic candidates are all based on the active ingredient PHAD, which is a synthetic version of MPLA, that is known to stimulate TLR-4. PHAD stimulation of TLR-4 leads to the production of multiple types of cytokines and chemokines which modulate the activity of the innate and adaptive immune response. Modulated activities may include stimulation and recruitment of infection fighting immune cells, down-regulation of inflammation, and/or upregulation of inflammation depending on the degree and nature of the stimulation which enables the multiple potential product candidates in development.

The current therapies being developed under the so-called Gemini project are:

- REVTx-300, which is being developed as a potential therapy for the treatment of acute and chronic organ disease including CKD, AKI and myocarditis.
- REVTx-100 is being developed as a prevention and treatment of infection.

The company just announced that studies have shown that Gemini priming reduces the inflammatory response in human peripheral blood mononuclear cells (PBMCs) that were exposed to clinically relevant molecules on inflammation. According to company management, in this study, human PBMCs were primed with either Gemini or placebo followed by challenge with clinically relevant promoter molecules of inflammation including high mobility box protein-1 (HMGB-1) and lipopolysaccharide (LPS) *in vitro*. HMGB-1 is an endogenous damage associated molecular pattern (DAMP) that is generated during tissue injury (e.g. during surgery) which drives the inflammatory response. LPS is an exogenous pathogen associated molecular pattern (PAMP) that is generated from a bacterial infection and drives the inflammatory response associated with infection (e.g. fever).

After exposure of Gemini-primed PMBCs to either HMGB-1 or LPS, levels of multiple proinflammatory and anti-inflammatory cytokines including IL-1 beta, TNF-alpha, IL-6, IL-1 Receptor Antagonist, and IL-10 were measured. Priming with Gemini significantly decreased proinflammatory cytokines and significantly increased anti-inflammatory cytokines, relative to placebo. According to management, this fundamental change in responsiveness at the cellular level demonstrates how Gemini will protect against inflammation-mediated damage. Revelation noted it intends to share the full results from this study in a future publication.

These results raise our optimism over the potential outcome from the ongoing, US-based Phase 1b clinical study to evaluate the potential of Gemini as a preconditioning treatment in patients with chronic kidney disease (CKD). This was extremely good news for the progression of this important treatment that has showed so much promise in earlier tests as we've discussed before.

According to the company, the multi-site, placebo-controlled Phase 1b clinical study is enrolling up to 40 subjects in up to 5 cohorts. The primary endpoint is evaluation of the safety and tolerability of a single dose of Gemini in patients with CKD. Secondary and exploratory endpoints will assess the pharmacokinetics, and the potential of Gemini to mobilize and attenuate the innate immune

response to stress by measuring several predictive biomarkers of efficacy. The company also noted that topline data from the trial is expected to be announced mid-2025.

As a reminder, the company previously announced data from its Phase 1 trial of Gemini. This study involved 40 healthy individuals between the ages of 18 and 55 who were given placebo, low, mid and high doses. The primary purpose was to determine what the appropriate dosage was to use for further studies as well as evaluating the safety of Gemini. Those goals were both met, with the company noting that Gemini was generally well tolerated, with adverse events increasing as the dose increased. It's important to note that Gemini administration did not result in any significant changes in clinical safety markers. The company also noted that the mid-level dose is now established as the maximum tolerated dose in healthy volunteers.

Another round of positive data from the upcoming Phase 1b study should then lead to, according to company management, a Phase 2 study of the treatment as a preconditioning treatment in patients with CKD to reduce the incidence, duration, and severity of acute kidney injury (AKI) in patients undergoing coronary artery bypass graft (CABG) and/or cardiac valve surgery.


As another reminder about issues we've written about, Gemini is also being developed for multiple indications, including as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program), and as pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program).

We are under no illusions that it's easy to bring new therapies all the way to commercialization and Revelation will undoubtedly face challenges, but we believe that REVB is worth a look by investors due to the potential of the treatments being investigated, the science that has already been established behind those treatments, and the experienced management team the company has, headlined by the CEO who has overseen six INDs and two marketing approvals—experience we believe is needed to shepherd these treatments through the gauntlet of the FDA.

PROJECTED INCOME STATEMENT & BALANCE SHEET

Revelation Income Statement and Balance Sheet						
	4Q2023A	**1Q2024A**	**2Q2024A**	**3Q2024A**	**4Q2024A**	**2025E**
Revenues	0	0	0	0	0	0
Operating Expenses						
Research and Development	1,059,984	717,582	1,394,929	830,981	605,504	2,543,117
General and Administrative	1,265,906	1,184,556	1,127,468	965,705	1,148,384	4,823,213
Total Operating Expenses	2,325,890	1,902,138	2,522,397	1,796,686	1,753,888	7,366,330
Gain/(Loss) from Operations	(2,325,890)	(1,902,138)	(2,522,397)	(1,796,686)	(1,753,888)	(7,366,330)
Other Income/(Expense)						
Change in fv of warrant liab.	68,202	68,427	4,416	6,041	2,557	2,634
Other income/(expense)	54,785	(847,722)	(5,871,838)	(450,920)	25,612	24,331
Total other income/(expense)	122,987	(779,295)	(5,867,422)	(444,879)	28,169	26,965
Net Income/(Loss)	(2,202,903)	(2,681,433)	(8,389,819)	(2,241,565)	(1,725,719)	(7,339,364)
Net Income/(Loss) per share	($8.33)	($2.46)	($5.13)	($0.84)	($10.06)	($38.90)
Shares Outstanding-diluted	264,537	1,089,833	1,635,234	2,679,941	171,510	188,661
Assets						
Current Assets:						
Cash and equivalents	11,991,701	14,551,740	12,073,058	6,541,052	6,499,018	6,174,067
Other current assets	155,824	71,876	125,743	117,846	66,699	69,367
Total current assets	12,147,525	14,623,616	12,198,801	6,658,898	6,565,717	6,243,434
Property and Equipment	65,084	77,994	70,774	81,242	56,332	55,205
Total Assets	12,212,609	14,701,610	12,269,575	6,740,140	6,622,049	6,298,639
Liabilities and SH Equity						
Current Liabilities:						
Accounts payable	1,359,898	1,681,665	1,281,323	3,127,348	783,621	791,457
Accrued expenses	1,152,460	620,280	8,454,139	934,372	1,127,800	1,139,078
Def. underwriting coms.	2,911,260	2,911,260	1,382,848	0	0	0
Warrant liabilities	141,276	15,260	10,844	4,803	2,246	2,291
Total current liabilities	5,564,894	5,228,465	11,129,154	4,066,523	1,913,667	1,932,826
Total Liabilities	5,564,894	5,228,465	11,129,154	4,066,523	1,913,667	1,932,826
Shareholder Equity						
Common Stock	265	1,633	1,643	4,292	522	265
Additional Paid-in Capital	32,114,552	37,620,047	37,677,132	41,449,244	45,213,498	47,474,173
Accumulated Deficit	(25,467,102)	(28,148,535)	(36,538,354)	(38,779,919)	(40,505,638)	(43,108,625)
Total Shareholder Equity	6,647,715	9,473,145	1,140,421	2,673,617	4,708,382	4,365,813
Total Liabilities and SE	12,212,609	14,701,610	12,269,575	6,740,140	6,622,049	6,298,639

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.